Jump to content

Umeclidinium bromide/vilanterol

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by DePiep (talk | contribs) at 20:41, 21 October 2017 (Licence EU: Add link to EMA licence page (EPAR), search by INN. (via JWB)). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Umeclidinium bromide/vilanterol
Umeclidinium bromide (TOP), vilanterol (BOTTOM)
Combination of
Umeclidinium bromideMuscarinic antagonist
VilanterolUltra-long-acting β2 agonist
Clinical data
Trade namesAnoro Ellipta
AHFS/Drugs.comanoro-ellipta
License data
Routes of
administration		Inhalation (DPI)
ATC code
Legal status
Legal status
Identifiers
KEGG

Umeclidinium bromide/vilanterol (trade name Anoro Ellipta) is a combination drug approved for the treatment of chronic obstructive pulmonary disease (COPD).[1][2] It is applied as an inhalation.

References

  1. ^ Feldman, GJ; Edin, A (2013). "The combination of umeclidinium bromide and vilanterol in the management of chronic obstructive pulmonary disease: Current evidence and future prospects". Therapeutic advances in respiratory disease. 7 (6): 311–9. doi:10.1177/1753465813499789. PMID 24004659.
  2. ^ "FDA Approves Umeclidinium and Vilanterol Combo for COPD". Medscape. December 18, 2013.
Stub icon

This drug article relating to the respiratory system is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Umeclidinium_bromide/vilanterol&oldid=806406980"